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cAMP-Epac Pathway Stimulation Modulate Connexin-43 and 
MicroRNA-21 Expression in Glioma Cells 
Introduction: Malignant astrocytic gliomas are the most common and lethal brain malignancies 
due to their refractory to the current therapies. Nowadays, molecular targeted therapy has 
attracted great attention in treatment of glioma. Connexin 43 (Cx43) and micro ribonucleic acid-
21(miR-21) are among molecules that are involved in glioma development and progression. 
These molecules showed potential to be as target molecules with regard to glioma. Some studies 
have reported that cyclic adenosine monophosphate (cAMP) signaling could be effective on 
Cx43 and miR-21 in tissues other than in brain. We investigate possible relationship between 
β-adrenergic receptor and its newly described downstream, exchange protein directly activated 
by cAMP (Epac) signaling pathway and expression of Cx43 and miR-21 in low (1321N1) and 
high grade (U87MG) glioma cell lines.
Methods: We treated cells with β-adrenergic agonist and Epac activator with and without adenyl 
cyclase inhibitor. Cx43 and miR-21 expression were measured with real-time PCR.
Results: Our data showed that in 1321N1 cells, β-adrenergic-Epac pathway stimulation up and 
down-regulated Cx43 and miR-21 expression respectively. Whereas, in U87MG cells these 
interventions had no effect on Cx43 and miR-21 expression.
Discussion: These findings demonstrate that low grade astrocytoma cells have better response to 
our pharmacological interventions.
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1. Introduction
rain tumors including glioma and glioblas-
toma are diverse groups of malignancies that 
remain unresponsive to conventional treat-
ment approaches, including radiotherapy and 
cytotoxic chemotherapy. So these tumors are 
coupled with a high mortality rate and poor survival. Mo-
lecular neuro-oncology has now started to elucidate signal-
ing pathways that may be amenable to molecular targeted 
therapy (Furnari et al., 2007). Previous studies demonstrat-
ed that some glial markers including Cx43 that down-regu-
lated in this pathophysiology changed in glioma (Huang et 
al., 1999). Cx43, the primary protein forming gap junction 
channels in astrocytes, has been probed to a great degree 
owing to its growth inhibitory effects (Kardamia et al., 
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2007). Reduction or loss of Cx43 expression which me-
diated cellular interconnection is commonly observed in 
glioma. Suggesting that the expression of Cx43 have in-
verse correlation with the degree of malignancy (Huang 
et al., 1999). Over-expression of Cx43 led to reduction of 
proliferation and formation of tumor (Huang et al., 1998). 
Phosphorylation of Cx43 by protein kinase C (PKC) de-
creases dye coupling in many cell types (Bao et al., 2004). 
MicroRNAs are small non-coding RNAs, which function 
in RNA silencing and post-transcriptional regulation of 
gene expression. Alteration in expression of microRNAs 
(miRNAs) has correlation with several cancers, including 
brain tumors and specifically glioma (Lawler et al., 2009). 
They can play both role of oncogenes or tumor suppres-
sors by binding to 3’ un-translated region (3’UTRs) of 
tumor-suppressor genes and oncogenes respectively (No-
vakova et al., 2009). MiR-21 is one of the miRNAs that 
up-regulated in glioma. One study suggested that aberrant-
ly expression of miR-21 may block expression of apop-
totic genes and thereby exert anti-apoptotic effect (Chan 
et al., 2005). Down-regulating of miR-21 inhibited epider-
mal growth factor receptor (EGFR) pathway and glioma 
growth. In combinational therapies with S-Trail, cytotoxic 
effect enhanced (Corsten et al., 2007; Zhou et al., 2010) 
and human glioblastoma cells become more sensitive to 
chemotherapy agents (Ren et al., 2010).
Given that the records in the Oncoming cancer profil-
ing database (http://www.oncomine.org) proposes that a 
major portion of gliomas express the beta 2 adrenergic 
receptor (ß2-AR) to a greater extent than in normal brain 
tissue. So this receptor stands for potential therapeutic 
target for treatment of these tumors (Toll et al., 2011). 
Some studies showed relationship between cAMP and 
Cx43 expression and gap junction gating in tissues such 
as heart (Xia et al., 2009). Also different lines of reports 
have showed relationship between cAMP level and 
miRNAs expression (Lu et al., 2009; Keller et al., 2012). 
Previous works have demonstrated that some effects of 
cAMP depend on its newly described downstream an-
dEpac pathway. In other words, besides protein kinase 
A (PKA), cAMP has another intracellular downstream 
pathway, (Epac), that mediate some effects of cAMP in 
mammalian cells (Bos, 2006). 
Considering the roles of cAMP signaling pathway, 
Cx43 and miR-21 in the pathogenesis of glioma we 
evaluate the effect of β-adrenergic receptor (βAR) and 
Epac signaling pathway stimulation on Cx43 and miR-
21 expression in glioma cells. 
2. Methods
2.1. Materials 
All drugs in this study including non-selective β ad-
renergic agonist, Isoproterenol hydrochloride (Iso) 
[16504], selective β2-AR agonist, Clenbuterol hydro-
chloride, (C5423), adenyl cyclase inhibitor, SQ 22,536 
(S 153), PKA specific inhibitor (H-89) [B1427], Epac-
specific activator 8-(4-chlorophenylthio)-2-O-methyl-
adenosine-3,5-cyclic monophosphate (8CPT) [C8988] 
were purchased from Sigma-Aldrich (USA). Qiazol and 
reverse transcriptase were purchased from Qiagen and 
vivantis respectively. Treatment condition wasthe same 
as what we performed in our previous study (Mostafavi 
et al., 2014).
2.2. Cell culture 
The human glioblasoma cell line U87MG and human 
astrocytoma cell line 1321N1 were obtained from the 
Stem Cell Technology Research Center, (Tehran, Iran) 
and were maintained in Dulbecco’s Modified Eagle Me-
dium (DMEM) containing 10% Fetal Bovine Serum 
(FBS) supplemented with 100 unit/ml penicillin and 50 
mg/ml streptomycin under a humidified atmosphere at 
5% CO2 and 37˚C temperature. Confluent monolayers 
were passaged routinely by trypsinization. Cells were 
plated for RNA extraction analysis in six-well plates. 
Cells were treated with 70-80% confluence following 
medium change with DMEM containing 1% FBS. 
2.3. Real-time RT PCR
The relative quantification of CX43 gene expression 
was carried out on treated cells and controls 24 hours 
after treatment. Total cellular messenger RNA (mRNA) 
was isolated using the Qiazol (Qiagen) according to 
manufacturer’s protocol and then used for complemen-
tary deoxyribonucleic acid (cDNA) synthesis by reverse 
transcriptase (vivantis Cat No: RTPL12). Hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) served as the ref-
erence gene. The primers used in the reactions had the 
following sequences: Cx43 forward: 5′- GAT GAG 
GAA GGA AGA GAA G -3′, Cx43 reverse: 5′- CGC 
TAG CTT GCT TGT TGT AA -3′, Epac2 forward: 
5′- CGA TTC ACT GAC TCC CTT AC -3′, Epac2 re-
verse: 5′- CTT CCA AAT GTG TGA TAG ATT AG -3′, 
HPRT1 forward: 5′- CCT GGC GTC GTG ATT AGT G 
-3′, HPRT1 reverse: 5′- TCA GTC CTG TCC ATA ATT 
AGT CC -3′. Gene expression levels were quantified by 
Rotor Gene 6000 (Corbett, Concorde, NSW, Australia). 
The relative expression ratio of Cx43 and HPRT1 in 
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U87MG and 1321N1 cells under control conditions and 
after 24h of treatment with our drugs were calculated us-
ing the relative expression software tool (REST). 
2.4. miRNA expression quantification
To evaluate miR-21 expression, real-time reverse tran-
scription polymerase chain reaction (RT PCR) was done 
for treated and control cells. After 24h, treated cells were 
collected for miRNA extraction by Qiazol reagent (Qia-
gen). cDNA synthesis was done using Stratagene real-
time PCR kit and according to manufacturer’s protocol. 
Briefly, after poly-adenylation of total RNAs, the cDNA 
was synthesized by adaptor primer provided by com-
pany.
The relative quantification of miRNAs in comparison 
with control cells was assessed by real-time RT PCR 
with Stratagene SYBR green master mix (Stratagene), 
according to the manufacturer’s instructions in a Rotor-
Gene 6000 system (Corbett, Concorde, NSW, Australia) 
[n=3]. The relative expression ratio of miRNAs under 
control conditions and after 24h of treatment with our 
drugs was normalized relative to U6 endogenous con-
trol and then was calculated using the REST. The prim-
ers used in the reactions had the following sequences: 
miR-21 sense: 5’-GAA TTC CGA TCT TAA CAG GCC 
AGA AAT GC-3’, miR-21 reverse: 5’-AGA TCT CCA 
CCA GAC AGA AGG ACC AGA GT-3’, U6 sense: 5’- 
CTC GCT TCG GCA GCA CA-3’, U6 reverse: 5’- AAC 
GCT TCA CGA ATT TGC GT-3’.
2.5. Statistical analysis 
The obtained data were analyzed by a statistical soft-
ware package (SPSS for Windows) and P-values<0.05 
were considered statistically significant. P-values less 
than 0.05 were considered as statistically significant. 
Asterisk (*) indicates that the result is significant. Each 
experiment repeated independently at least three times.
3. Results
3.1. EPAC2 expression in glioma cell lines (U87MG 
and 1321N1) under different conditions
Based on previous reports EPAC2 is present in devel-
oping and mature brain (Bos et al., 2006). To check ex-
pression of EPAC2 in U87MG and 1321N1 cell lines, 
we performed RT-PCR analysis. As illustrated in Figure 
1, we found that these glioma cell lines express EPAC2 
mRNA. However, our treatments did not change signifi-
cantly the level of EPAC2 mRNA (Figure 1).
3.2. Effect of non-selective βAR stimulation and 
Epac signaling pathway on Cx43 mRNA expres-
sion
In 1321N1 cells, Iso significantly upregulates the Cx43 
mRNA level (P<0.01). Pretreatment of cells with SQ 
for 45 minutes before adding the Iso, showed Adenyl-
ate Cyclase (AC) inhibition and blocked Iso effect on 
the Cx43 mRNA expression. Selective Epac stimulation 
using 8CPT did not change the Cx43 mRNA expression 
compared to un-treated group (Figure 2A). In U87MG 
cells, beta agonist treatment had no significant effect 
on the Cx43 expression. As expected, when these cells 
pretreated with AC inhibitor, no effect was detected. Fi-
nally, U87MG cells were treated with 25 μg/ml of 8CPT, 
no significantly change in Cx43 mRNA was detected 
(Figure 2B). These data suggested that non-selective 
βA stimulation only increases Cx43 mRNA level in low 
grade astrocytoma cell line (1321N1) and Epac stimula-
tion had no effect on Cx43 expression in both low and 
high grade glioma cell lines.
3.3. Effect of selective β2AR stimulation and Epac 
signaling pathway on miR-21 expression
To evaluate the selective β2AR stimulation effect on 
miR-21 expression, we inevitably used only 1321N1 
cells, because previous studies reported that U87MG 
cells do not express β2AR (Toll et al., 2011). After 
24 hours treatment, 10 μg/ml of selective β2-AR ago-
nist significantly decreased miR-21 expression level in 
1321N1 cells (P<0.05). Treating cells with Clenbuterol 
20 μg/ml, decreased miR-21 expression (P<0.05), but 
this effect was not dose dependent. Pre-treatment with 
AC inhibitor, reversed selective β2AR stimulation ef-
fect. Application of Epac selective agonist decreased 
Figure 1. Detection of endogenously expressed Epac2 in 
1321N1 and U87MG cell lines (165 base pairs) in un-treated 
and treated cells with 20 μg/ml Iso and 25μg/ml selective 
Epac activator (8CPT). HPRT1 was used as internal control 
(100 bp).
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significantly miR-21 expression in this cell (P<0.05) 
(Figure 3). 
3.4. Effect of non-selective βAR stimulation and 
Epac signaling pathway on miR-21 expression in 
U87MG cells
Based on previous reports that showed functional rela-
tionship between cAMP and some miRNAs expression 
(Lu et al., 2009; Keller et al., 2012), here we evaluated 
putative regulation of miR-21 by stimulation of non-
selective βAR and Epac signaling pathway in U87MG 
cells by real time-PCR. After 24 hours treatment, al-
though the amount used (20 μg/ml of Iso and 25 μg/ml 
of 8CPT) decreased miR-21 expression, but these effects 
were not significant (Figure 4). 
4. Discussion
4.1. cAMP-Epac effects on Cx43 expression
In our study, βAR stimulation increased Cx43 mRNA 
level in 1321N1 astrocytoma cells, but Epac activator 
did not boost the βAR effect. In addition, in U87MG 
cells Isoproterenol treatment and Epac signaling path-
way stimulation had no effect on Cx43 mRNA level 
significantly. These results suggest that Epac signaling 
pathway has no role on βAR stimulation, and malignan-
cy severity may change the rate of response to treatment.
Cx43 is one of the brain and astrocytes markers. Al-
teration of this marker resulted in progression of glioma 
due to its physiological roles (Huang et al., 1999). Previ-
ous studies demonstrated that Cx43 controls cell growth 
and has tumor suppressor and growth inhibitory effects 
(Iacobas et al., 2012). Decreasing levels of Cx43 and 
gap junction interconnection are commonly observed in 
glioma (Huang et al., 1999) and up-regulation of Cx43 
seem to had suppressor effect on tumor (Sanchez-Al-
varez et al., 2006). In order to find a treatment solution 
for malignant brain tumors based on targeted molecular 
agents, researches have used differentiation agents such 
as cAMP and its related signaling components (Toll et 
al., 2011,Kurino et al., 2002). Change in cAMP and its 
down-stream signaling pathway including PKA and 
Epac have demonstrated to affect connexin level. This 
signaling pathway has also been shown to be a major 
modulator of Cx43 in the heart (Somekawa et al., 2005). 
However, the molecular nature of βAR stimulation and 
cAMP derivative-induced effect on Cx43 expression in 
glioma cells were not evaluated. Previous researches 
showed that Cx43 expression level was changed in some 
pathophysiologic conditions including glioma (Huang 
et al., 1999). Studies on peripheral organs like heart 
showed that activation of cAMP and its down-stream 
pathways may affect Cx43 expression (Somekawa et al., 
2005). These results suggest that cAMP signaling only 
up-regulate Cx43 in low grade astrocytoma cells but not 
in malignant glioma.
We also found that βAR stimulation enhanced Cx43 
expression via cAMP activation in low grade astrocy-
toma cell line. However, Epac selective agonist did not 
Figure 2. Non- selective βAR and Epac pathway stimulation 
effects on Cx43 mRNA expression. 1321N1 (A) and U87MG 
(B) cells treated with Iso (20 μg/ml) [βAR agonist], Iso (20 
μg/ml) + AC inhibitor (20 μg/ml) [Iso +SQ] and 8CPT (25 
μg/ml) [Epac activator] for 24 hours and changes in tran-
script amount were determined by real-time quantitative 
PCR (qPCR). It was revealed that only Iso increased Cx43 ex-
pression in 1321N1 cells. (*P< 0.01, Comparison were done 
relative to untreated controls).
Figure 3. Selective β2-AR and Epac pathway stimulation ef-
fects on miR-21 expression. 1321N1 cells treated with 10 (B1) 
and 20 (B2) μg/ml of Clenbuterol, 10 μg/ml of Clenbuterol 
+ 20 μg/ml of adenyl cyclase inhibitor (sterol biosynthesis 
inhibitor; SB1) and 25 μg/ml of 8CPT (Epac activator). It was 
observed that both doses of Clenbuterol and 8CPT could 
down regulate miR-21 expression. (*: P< 0.05, Comparisons 
were done relative to untreated controls).
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change Cx43 mRNA expression, in our previous study 
(Mostafavi et al., 2014), 25 μg/ml selective Epac ago-
nist led to enhancement of Cx43 protein but not Cx43 
mRNA in 1321N1 cells. Thus, we concluded that this 
amount of Epac agonist presumably had post-transla-
tional effect instead of transcriptional effect. 
4.2. cAMP-Epac effects on miR-21 expression
According to our findings, lower doses of Clenbuterol 
(10 and 20 μg/ml) down-regulated miR-21 expression 
significantly, although it was without dose dependency. 
As high grade U87MG cells do not express β2-AR, so 
we evaluated cAMP signaling pathway stimulation ef-
fects with Isoproterenol and selective Epac activator on 
miR-21 expression and the results showed that none of 
our treatments had significant effect on this miRNA ex-
pression.
MiRNA genes are located in fragile sites of the genome 
and this provides an adequate testimony for the roles of 
miRNAs in tumors including glioma (Farazi et al., 2011). 
Several reports have shown the potential use of miRNA-
based approach in glioma therapy (Silber et al., 2009). 
MiR-21 being one of the most up-regulated miRNAs 
in gliomas, with anti-apoptotic and pro-invasive func-
tions, appears to be an automatic choice for therapeutic 
interventions (Chan et al., 2005; Papagiannakopoulos et 
al., 2008). Our previous data (Mostafavi et al., 2014), 
showed that selective β2-AR stimulation with the high-
est dose of Clenbuterol (40 μg/ml) led to up-regulation 
of miR-451 in low grade 1321N1 astrocytoma cells. It 
seems that pharmacological interventions are effective 
only in low grade astrocytoma and for molecular target 
therapy in high grade glioma, other strategies such as in-
terference RNA may be more effective. 
In conclusion, this study revealed that Cx43 and miR 
21 expression in high grade glioma did not modulated 
with cAMP-Epac signaling pathway. However, pharma-
cological interventions in low grade astrocytoma could 
be effective on Cx43 and miR 21 expression. Modula-
tion of mentioned molecules may open interesting new 
therapeutic approaches for glioma, although further 
studies are needed to expose complex relationship and 
their long term regulation and to confirm these findings 
for the eventual applications in clinics. 
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